MedTrace Logo

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

NCT06112327 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2026-04-08

No results posted yet for this study

Summary

LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.

Conditions

Sponsors & Collaborators

  • Verve Therapeutics, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-09
Primary Completion
2039-10-31
Completion
2039-10-31

Countries

  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06112327 on ClinicalTrials.gov